Spanish Series of Patients Treated With the Radionuclide Lutetium177 (SEPTRALU)

Sociedad Española de Medicina Nuclear e Imagen Molecular

Status: Enrolling

Conditions: Intestinal Diseases; Neoplasms by Site; Neoplasms, Nerve Tissue; Endocrine Gland Neoplasms; Neuroendocrine Tumors; Digestive System Diseases; Pancreatic Disease; Digestive System Neoplasms; Neoplasms, Germ Cell and Embryonal; Gastrointestinal Neoplasms; Endocrine System Diseases; Neoplasms by Histologic Type; Gastrointestinal Disease; Intestinal Neoplasms; Neoplasms; Neuroectodermal Tumors; Stomach Neoplasms; Pancreatic Neoplasms

Treatments: Device: Lutetium [177Lu] oxodotreotide/dotatate

Study type: Observational

Funder types: Other

Identifiers

NCT04949282

SEM-LUT-2020-01

Details and patient eligibility

About

This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.

Full description

Patient data will be collected from medical records after obtaining consent and retrospectively.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent must be obtained prior to any data collection.
• Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour
• Aged ≥18 years.

Exclusion criteria

• None

Trial design

5,000 participants in 1 patient group

Lutathera

Treatment:

Device: Lutetium [177Lu] oxodotreotide/dotatate

Device: Lutetium [177Lu] oxodotreotide/dotatate